Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 6/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793931 | 0.73 | DYRK1A (0.50) | DYRK1AKDM4ENPC1RAB9AMAPT | |
| SCHEMBL17997425 | 0.70 | MTNR1A (0.60) | DYRK1AKDM4ENPC1RAB9AMAPT | |
| SCHEMBL219770 | 0.67 | KDM4E (0.48) | DYRK1AKDM4ENPC1RAB9AMAPT | |
| SCHEMBL3203569 | 0.67 | CA12 (0.54) | DYRK1AKDM4ENPC1RAB9AMAPT | |
| SCHEMBL219771 | 0.67 | AKR1C3 (0.56) | DYRK1AKDM4ENPC1RAB9AMAPT | |
| SCHEMBL3155955 | 0.66 | CA12 (0.53) | DYRK1AKDM4ENPC1RAB9AMAPT | |
| SCHEMBL17378054 | 0.66 | CA4 (0.61) | KDM4ENPC1RAB9AMAPTBRD4 | |
| SCHEMBL17997427 | 0.66 | DYRK1A (0.52) | DYRK1ABRD4DRD2CA12CA1 | |
| SCHEMBL17378162 | 0.65 | CA4 (0.60) | KDM4ENPC1RAB9AMAPTDRD2 | |
| SCHEMBL4488719 | 0.65 | BRD4 (0.60) | KDM4ENPC1RAB9AMAPTBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | DYRK1A 754/4885KDM4E 2167/4885NPC1 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.